Other Information .
+Added: (a) Amendment to License Agreement
+Added: On August 7, 2025, we entered into Amendment No.
+Added: 4 (the “Amendment”) to our license agreement, dated December 17, 2022, as previously amended (the “Agreement”) with Berlin-Chemie AG, an affiliate of the Menarini Group (“Menarini”), pursuant to which we granted Menarini a non-exclusive license to, among other things, develop and commercialize selinexor for all human oncology indications in Europe (including the United Kingdom), Latin America, certain Middle East and Africa regions and other key countries.
+Added: Upon our request, under the terms of the Amendment, Menarini agreed to anticipate the payment, and to actualize the value, of the next sales performance milestone payment.
+Added: Accordingly, Menarini will pay us a one-time cash payment of $4.24 million in lieu of our right to receive a $5.0 million payment from Menarini upon the achievement of a net sales performance milestone based on net sales within a calendar year.
+Added: We expect to file the Amendment as an exhibit to our Quarterly Report on Form 10-Q for the three months ended September 30, 2025.
(c) Director and Officer Trading Arrangements
3 unchanged sentences
Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
−Removed: During the first quarter of 2025, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
−Removed: Restated Certificate of Incorporation of the Registrant, as amended
−Removed: Non-Employee Director Compensation Policy
+Added: During the second quarter of 2025, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
+Added: Side Letter Amendment to License Agreement, dated June 30, 2025, by and between Antengene Therapeutics Limited and the Registrant
Amendment No.
−Removed: 3 to License Agreement, dated March 4, 2025, by and between the Registrant and Berlin-Chemie AG
+Added: 3 to the Karyopharm Therapeutics Inc.
+Added: 2022 Equity Incentive Plan (incorporated herein by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A (File No.
+Added: 001-36167) filed with the SEC on April 14, 2025)
Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
11 unchanged sentences
KARYOPHARM THERAPEUTICS INC.
+Added: August 11, 2025
/s/ Richard Paulson
2 unchanged sentences
(Principal executive officer)
+Added: August 11, 2025
/s/ Lori Macomber
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.